Articles from AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

PRESS RELEASE

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference